Clinical trial NCT03333096: Assessing Neurovisual Function in Patients With Cognitive Impairment
Official title: Assessing Neurovisual Function in Patients With Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glaucoma
Mild Cognitive Impairment
Glaucoma and Mild Cognitive Impairment
Healthy
Keywords: Glaucoma
Mild Cognitive Impairment
Ocusweep
Reaction Time
Neuropsychology
Dementia
Alzheimer's Disease
Brain Diseases
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Ocuspecto Oy
name: European Commission
First posted: 2017-11-06
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The aim of this study is to measure fitness to drive in patients with a visual and a cognitive impairment. To do so, Ocusweep is used in patients with glaucoma and Mild Cognitive Impairment. The participants will be divided over four groups; patients with glaucoma, patients with cognitive impairment, patients with both and a healthy control group. Differences in performance on Ocusweep in the four different groups of participants are expected. These effects may be related to fitness to drive, which is why those results will be compared to traditional neuropsychological measures of fitness to drive. the hypothesis of the current study is that the Ocusweep performance is related to performance on other measures of fitness to drive.


Eligibility criteria: Inclusion Criteria:

* Be at least 65 years old
* Fit into one of the four groups of participants
* No other eye diseases than glaucoma
* Still be able to and allowed to drive a car
* Be able to visit the Turku Driver's Clinic for testing

Exclusion Criteria:

* A history of neurological disorders, depression or anxiety
* Motor problems
* Visual acuity less than 0.5
* Score over 6 in Geriatric Depression Scale questionnaire (GDS 15)

Primary outcomes:
measure: Perception speed
timeFrame: 2 years
measure: Evidence of cognitive impairment measured by MoCA-test
timeFrame: 2 years
measure: Evidence of impaired attentional ability - Cognitive profile
timeFrame: 2 years
measure: Evidence of impaired Executive Functioning - Cognitive profile 1/2
timeFrame: 2 years
measure: Evidence of impaired Executive Functioning - Cognitive profile 2/2
timeFrame: 2 years
measure: Evidence of impaired Visuoconstructive abilities - Cognitive profile
timeFrame: 2 years
measure: Evidence of slow reaction time - Cognitive profile
timeFrame: 2 years
measure: Evidence of impaired visual attention measured by UFOV-test - Cognitive Profile
timeFrame: 2 years
measure: Evidence of glaucomatous visual field defects 1/2
timeFrame: 2 years
measure: Evidence of glaucomatous visual field defects 2/2
timeFrame: 2 years
measure: Contrast Sensitivity - Ocusweep
timeFrame: 2 years
measure: Visual Acuity- Ocusweep
timeFrame: 2 years
measure: Visual Search - Ocusweep Neural
timeFrame: 2 years
measure: Memory guided saccades - Ocusweep Neural
timeFrame: 2 years
measure: Anti-saccades - Ocusweep Neural
timeFrame: 2 years
measure: Prosaccade - Ocusweep Neural
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Eija Vesti, Dr
role: PRINCIPAL_INVESTIGATOR
References: